244 related articles for article (PubMed ID: 34110532)
1. Real-world safety and effectiveness of nivolumab for recurrent or metastatic head and neck cancer in Japan: a post-marketing surveillance.
Tahara M; Kiyota N; Nibu KI; Akamatsu A; Hoshino T; Hayashi R
Int J Clin Oncol; 2021 Sep; 26(9):1619-1627. PubMed ID: 34110532
[TBL] [Abstract][Full Text] [Related]
2. Safety of nivolumab monotherapy in five cancer types: pooled analysis of post-marketing surveillance in Japan.
Hiraizumi K; Honda C; Watanabe A; Nakao T; Midorikawa S; Abe H; Matsui N; Yamamoto T; Sakamoto T
Int J Clin Oncol; 2024 Jul; 29(7):932-943. PubMed ID: 38844668
[TBL] [Abstract][Full Text] [Related]
3. Real-world safety and effectiveness of nivolumab for advanced renal cell carcinoma in Japan: a post-marketing surveillance.
Uemura H; Tomita Y; Nonomura N; Yoshizaki K; Nakao T; Shinohara N
Int J Clin Oncol; 2022 Jun; 27(6):1061-1067. PubMed ID: 35441907
[TBL] [Abstract][Full Text] [Related]
4. Safety and effectiveness of nivolumab in Japanese patients with malignant melanoma: Final analysis of a post-marketing surveillance.
Uhara H; Tsuchida T; Kiyohara Y; Akamatsu A; Sakamoto T; Yamazaki N
J Dermatol; 2022 Sep; 49(9):862-871. PubMed ID: 35607248
[TBL] [Abstract][Full Text] [Related]
5. Real-world safety of nivolumab in patients with non-small-cell lung cancer in Japan: Postmarketing surveillance.
Yamamoto N; Nakanishi Y; Gemma A; Nakagawa K; Sakamoto T; Akamatsu A; Ohe Y
Cancer Sci; 2021 Nov; 112(11):4692-4701. PubMed ID: 34431585
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and safety of nivolumab in patients with head and neck cancer in Japanese real-world clinical practice: a multicenter retrospective clinical study.
Hanai N; Shimizu Y; Kariya S; Yasumatsu R; Yokota T; Fujii T; Tsukahara K; Yoshida M; Hanyu K; Ueda T; Hirakawa H; Takahashi S; Ono T; Sano D; Yamauchi M; Watanabe A; Omori K; Yamazaki T; Monden N; Kudo N; Arai M; Sakurai D; Asakage T; Doi I; Yamada T; Homma A
Int J Clin Oncol; 2021 Mar; 26(3):494-506. PubMed ID: 33219460
[TBL] [Abstract][Full Text] [Related]
7. Post-marketing surveillance of the safety and effectiveness of nivolumab for classic Hodgkin lymphoma in Japan.
Kawasaki A; Hatake K; Matsumura I; Izutsu K; Hoshino T; Akamatsu A; Kakuuchi A; Tobinai K
Int J Hematol; 2024 Jun; 119(6):667-676. PubMed ID: 38521840
[TBL] [Abstract][Full Text] [Related]
8. Real-world safety and effectiveness of nivolumab in Japanese patients with unresectable advanced or recurrent gastric/gastroesophageal junction cancer that has progressed after chemotherapy: a postmarketing surveillance study.
Yamaguchi K; Boku N; Muro K; Yoshida K; Baba H; Tanaka S; Akamatsu A; Sano T
Gastric Cancer; 2022 Jan; 25(1):245-253. PubMed ID: 34581902
[TBL] [Abstract][Full Text] [Related]
9. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
[TBL] [Abstract][Full Text] [Related]
10. Real-World Experience of Immunotherapy from India in Recurrent Squamous Cell Carcinoma of Head and Neck Cancer.
Abbas W; Gupta S; Goel V; Rao RR; Pankaj P; Tripathi D; Patil PP; Popli S
South Asian J Cancer; 2021 Apr; 10(2):72-75. PubMed ID: 34568218
[No Abstract] [Full Text] [Related]
11. Two-year follow-up of a randomized phase III clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141).
Yen CJ; Kiyota N; Hanai N; Takahashi S; Yokota T; Iwae S; Shimizu Y; Hong RL; Goto M; Kang JH; Li WSK; Ferris RL; Gillison M; Endo T; Jayaprakash V; Tahara M
Head Neck; 2020 Oct; 42(10):2852-2862. PubMed ID: 32583557
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival.
Mandala M; Larkin J; Ascierto PA; Del Vecchio M; Gogas H; Cowey CL; Arance A; Dalle S; Schenker M; Grob JJ; Chiarion-Sileni V; Marquez-Rodas I; Butler MO; Di Giacomo AM; Lutzky J; De La Cruz-Merino L; Atkinson V; Arenberger P; Hill A; Fecher L; Millward M; Khushalani NI; de Pril V; Lobo M; Weber J
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34452930
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of nivolumab affected by prior cetuximab use and neck dissection in Japanese patients with recurrent or metastatic head and neck cancer: results from a retrospective observational study in a real-world setting.
Kariya S; Shimizu Y; Hanai N; Yasumatsu R; Yokota T; Fujii T; Tsukahara K; Yoshida M; Hanyu K; Ueda T; Hirakawa H; Takahashi S; Ono T; Sano D; Yamauchi M; Watanabe A; Omori K; Yamazaki T; Monden N; Kudo N; Arai M; Yonekura S; Asakage T; Fujiwara A; Yamada T; Homma A
Int J Clin Oncol; 2021 Jun; 26(6):1049-1056. PubMed ID: 33830342
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial.
Haddad R; Concha-Benavente F; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Kasper S; Vokes EE; Worden F; Saba NF; Tahara M; Jayaprakash V; Lynch M; Li L; Gillison ML; Harrington KJ; Ferris RL
Cancer; 2019 Sep; 125(18):3208-3218. PubMed ID: 31246283
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
Ferris RL; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Harrington K; Kasper S; Vokes EE; Even C; Worden F; Saba NF; Iglesias Docampo LC; Haddad R; Rordorf T; Kiyota N; Tahara M; Monga M; Lynch M; Geese WJ; Kopit J; Shaw JW; Gillison ML
N Engl J Med; 2016 Nov; 375(19):1856-1867. PubMed ID: 27718784
[TBL] [Abstract][Full Text] [Related]
16. Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial.
Kudo T; Hamamoto Y; Kato K; Ura T; Kojima T; Tsushima T; Hironaka S; Hara H; Satoh T; Iwasa S; Muro K; Yasui H; Minashi K; Yamaguchi K; Ohtsu A; Doki Y; Kitagawa Y
Lancet Oncol; 2017 May; 18(5):631-639. PubMed ID: 28314688
[TBL] [Abstract][Full Text] [Related]
17. Pooled analysis of nivolumab treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck in the United States and Germany.
Singh P; McDonald L; Waldenberger D; Welslau M; von der Heyde E; Gauler T; Dietz A
Head Neck; 2021 Nov; 43(11):3540-3551. PubMed ID: 34487397
[TBL] [Abstract][Full Text] [Related]
18. Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: a retrospective multi-center study by the Turkish Oncology Group (TOG).
Akyildiz A; Guven DC; Koksal B; Karaoglan BB; Kivrak D; Ismayilov R; Aslan F; Sutcuoglu O; Yazici O; Kadioglu A; Alan O; Majidova N; Erciyestepe M; Ozcan E; Akdag G; Taban H; Kaya AO; Guliyev M; Yildirim N; Sakalar T; Yazilitas D; Unal C; On S; Biter S; Demirci NS; Senler FC; Kemal Y; Halil OD; Gullu I; Aksoy S
Eur Arch Otorhinolaryngol; 2024 May; ():. PubMed ID: 38795147
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma.
Zargar M; McFarlane T; Chan KKW; Wong WWL
Oncologist; 2018 Feb; 23(2):225-233. PubMed ID: 29021380
[TBL] [Abstract][Full Text] [Related]
20. Real-World Outcomes and Prognostic Factors in Patients Receiving Nivolumab Therapy for Recurrent or Metastatic Head and Neck Carcinoma.
Hori R; Shinohara S; Kojima T; Kagoshima H; Kitamura M; Tateya I; Tamaki H; Kumabe Y; Asato R; Harada H; Kitani Y; Tsujimura T; Honda K; Ichimaru K; Omori K
Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31500103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
